AstraZeneca Establishes Sixth Global R&D Center in Beijing to Accelerate AI-Driven Drug Discovery
核心洞察
AstraZeneca officially opened its sixth global strategic R&D center in Beijing's BioPark, marking the company's second facility in China alongside its Shanghai center.
The new facility will leverage Beijing's artificial intelligence capabilities and scientific ecosystem to accelerate development of innovative next-generation drugs.
The center will collaborate with AstraZeneca's Shanghai R&D facility to lead drug discovery and clinical development efforts, translating innovations into medicines.
AstraZeneca officially opened its new global research and development center in Beijing on Saturday, establishing the British pharmaceutical giant's sixth global strategic R&D facility and second in China. The center, located in the BioPark of the Beijing Economic-Technological Development Area (BDA), represents a significant expansion of the company's research capabilities in the region.
Strategic Focus on AI-Enhanced Drug Development
The Beijing facility will harness the city's scientific ecosystem and artificial intelligence strengths to accelerate the development of innovative next-generation drugs. According to He Jing, AstraZeneca's global senior vice president and president of R&D China, the center will work in close collaboration with the company's existing global strategic R&D center in Shanghai to lead drug discovery and clinical development efforts.
"New drug R&D is the core driver of the pharmaceutical industry. Through collaborations with ecosystem partners, we aim to achieve strong synergies by fully leveraging our respective advantages," He Jing stated during the opening ceremony.
Leveraging Beijing's Biomedical Ecosystem
The new center is strategically positioned to benefit from the BDA's robust research and development infrastructure. He Jing emphasized that the Beijing facility will enhance cooperation with research hospitals, universities, and biotech companies within the area's comprehensive ecosystem.
The BDA serves as a key hub for high-end industries and the biomedical sector, hosting over 5,000 biopharmaceutical companies. The area encompasses both global pharmaceutical giants including Pfizer, Bayer, and Sanofi, as well as local players such as Beijing Tide Pharmaceutical Co., Ltd. and Youcare Pharmaceutical Group (搜索), creating a complete healthcare industrial chain.
Recent Innovation Approvals
The BDA's growing significance in pharmaceutical innovation is evidenced by recent regulatory approvals. Since 2025, the area has seen the approval of two innovative drugs and three innovative medical devices, demonstrating the region's capacity for bringing novel therapeutics to market.
The establishment of AstraZeneca's Beijing R&D center underscores the company's commitment to accelerating the translation of scientific innovations into medicines through strategic partnerships and access to China's advancing biotechnology landscape.